Want to see QNCX full AI Analyst Report?
QNCX Stock Chart & Stats
$17.86
-$0.43(-2.32%)
At close: 4:00 PM EDT
$17.86
-$0.43(-2.32%)
Day’s Range― - ―
52-Week Range$15.10 - $909.80
Previous CloseN/A
Volume15.25K
Average Volume (3M)29.96K
Market Cap
$32.96M
Enterprise Value-$8.44
Total Cash (Recent Filing)$115.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 18, 2026EPS Estimate
-9.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-68.91
Shares Outstanding1,017,063
10 Day Avg. Volume39,771
30 Day Avg. Volume29,956
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$85.25Price Target Upside377.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-10.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Expansion And Funded RunwayThe Orphai acquisition brings a clinical-stage inhaled rapamycin program (LAM-001) and orphan indications, materially broadening Quince’s R&D portfolio. The concurrent up-to-$187M PIPE provides a multi-year funding runway toward late-decade Phase 2 readouts, reducing immediate financing risk and enabling program progression.
Nasdaq Listing MaintainedRegaining Nasdaq compliance removes delisting risk and preserves access to public equity markets. This durable outcome supports liquidity, future capital raises, and investor visibility—critical for a pre-revenue biotech that depends on public financing to fund clinical development over multiple years.
Low Financial LeverageMinimal debt exposure lowers fixed financial obligations and reduces bankruptcy risk relative to leveraged peers. For a development-stage company this structural conservatism preserves flexibility to prioritize R&D and negotiate non-dilutive or structured financing, supporting long-term program execution.
Bears Say
Pre-revenue With Sustained Cash BurnQuince remains pre-commercial with persistent negative operating and free cash flows, implying continued reliance on external financing. Structural cash burn of ~-$40M TTM increases dilution risk, constrains strategic optionality if markets tighten, and means program timelines hinge on successful funding execution.
Equity Volatility And Dilution HistoryLarge swings in stockholders’ equity reflect prior dilution, sizable financings, and accumulated losses. This pattern signals that future capital needs are likely to be met via equity instruments, which can materially dilute existing holders and create governance and valuation volatility over the medium term.
Major Leadership And Governance ChangeA planned leadership transition to the Orphai team constitutes a structural change in strategy and execution. New management and board composition can accelerate integration but also introduces execution risk, potential cultural shifts, and governance adjustments that materially affect pipeline prioritization and investor alignment over the medium term.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $15.10 and its highest was $909.80 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $32.96M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 94 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Aug 11, 2026. The company reported -$12.31 earnings per share for the quarter, beating the consensus estimate of -$28.02 by $15.71.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -9.95.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 1,017,063 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$12.31 in its last earnings report, beating expectations of -$28.02. Following the earnings report the stock price went up 6.786%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quince Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.25 (377.32% Upside)
$85.25 (377.32% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 16.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.79%
Trailing 12-Months
Company Description
Quince Therapeutics
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$85.25
▲(377.32% Upside)
Technical Analysis
Ownership Overview
50.74% Insiders
0.02% Mutual Funds
0.39% Other Institutional Investors
48.57% Public Companies and
Individual Investors